



# Garry Boyle, Innovation Adviser at Innovate UK EDGE

"NLSQL is a Business Intelligence software solution, that empowers clinicians with intuitive search to poorly-accessible data, leading to make faster and more accurate clinical decisions, particularly for more complex patients with multiple concurrent

chronic conditions following emergency admissions. Using NLSQL key stakeholders can detect where to focus resources to bring the best patients outcomes"



Federal Ministry of Education and Research

# **German Federal Ministry of Education and Research**

"Medical Business Intelligence" is the first specialized interface between medical staff and databases. Doctors and nursing staff can intuitively extract relevant information from the generated data using a chat interface (known from "Whatsapp" or similar chat systems) without learning complex syntax. Through Natural Language Processing NLSQL Healthcare BI understands the relationships and connections in spoken and written natural language."

<ul> <li>maxis-demo Chat</li> <li>Method Chat</li> <li>Method</li></ul>	<ul> <li>Verify TAY PM</li> <li>What are subject lids who encounter with hemoglobin decreased adverse events?</li> <li>maxis-demo 147 PM</li> <li>A few options are found, please choose what you need</li> <li>DECREASED HEMOGLOBIN ['AE'; AETERM'</li> <li>DECREASED HEMOGLOBIN FROM BASELINE ['AE'; AETER</li> <li>Poins 147 PM</li> <li>subjects lids adverse events [[['AE'; AETERM':DECREASED HEMOGLOBIN]]]</li> <li>maxis-demo 147 PM</li> <li>Beads on the data; bus luplects with DECREASED HEMOGLOBIN]]</li> <li>maxis-demo 147 PM</li> <li>Beads on the data; bus luplects with DECREASED HEMOGLOBIN]</li> <li>maxis-demo 147 PM</li> <li>Beads on the data; bus luplects with DECREASED HEMOGLOBIN]</li> <li>maxis-demo 147 PM</li> <li>Beads on the data; bus luplects with DECREASED HEMOGLOBIN]</li> <li>maxis-demo 147 PM</li> <li>Beads 1147 PM</li> <li>Analytics</li> <li>maxis-demo 147 PM</li> <li>Beads 1147 PM</li> <li>Manalytics</li> <li>maxis-demo 147 PM</li> <li>Beads 1147 PM</li> <li>Maxis-demo 147 PM</li> <li>Beads 1147 PM</li> <li>Manalytics</li> <li>maxis-demo 147 PM</li> <li>Beads 1147 P</li></ul>	48	maxis-demo ···· –	
What are subject ids who encounter with hemoglobin decreased adverse events?         Image: demo 147 PM         A few options are found, please choose what you need         DECREASED HEMOGLOBIN   'AE':AETERM'         DECREASED HEMOGLOBIN   'AE':AETERM'         DECREASED HEMOGLOBIN   'AE':AETERM'         DECREASED HEMOGLOBIN PROM BASELINE   'AE':AETER         Image: demo 147 PM         subjects ids adverse events [[['AE':AETERM':DECREASED HEMOGLOBIN]]]         Image: demo 147 PM         Based on the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject IDs:         MS2038001-1234, MS2038001-5678, MAXIS-XYZ-008-9012.         Image: demo 147 PM         Report       A lanalytics         Image: demo 147 PM         Image: demo 147 PM         Malanalytics       Identifying subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and	What are subject ids who encounter with hemoglobin decreased adverse events?         Image: Adverse events 147 PM         Image: Decretation 147 PM         Based on the data, the subjects with DECREASED HEMOGLOBIN]         Image: Decretation 147 PM         Based on the data, the subjects with DECREASED HEMOGLOBIN]         Image: Decretation 147 PM         Based on the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS203B001 and MAXIS-XYZ-008 studies are identified by the following subject ID::         Image: Decretation 147 PM         Image: Decretation 14			
A few options are found, please choose what you need         DECREASED HEMOGLOBIN ['AE';AETERM']         DECREASED HEMOGLOBIN ['AE';AETERM']         DECREASED HEMOGLOBIN ['AE';AETERM']         Decreased memoslobin ['AE';AETERM']         Based on the data, the subjects with DECREASED HEMOGLOBIN]]]         Image: dom the data, the subjects with DECREASED HEMOGLOBIN]]]         Image: dom the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject ID::         MS2038001-1234, MS2038001-5678, MAXIS-XYZ-008-9012.         Image: dom the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject ID::         MS2038001-1234, MS2038001-5678, MAXIS-XYZ-008-9012.         Image: dom the data, the subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers and analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and	A few options are found, please choose what you need         DECREASED HEMOGLOBIN   'AE 'AETERM'         DECREASED HEMOGLOBIN FOM BASELINE   'AE 'AETER         Image: Denis 147 PM         subjects ids adverse events [[[AE':AETERM:DECREASED HEMOGLOBIN]]]         Image: Denis 147 PM         Based on the data, the subjects with DECREASED HEMOGLOBIN]         Image: Denis 147 PM         Based on the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS203B001 and MAXIS-XYZ-008 studies are identified by the following subject ID: MS203B001-1234, MS203B001-5678, MAXIS-XYZ-008-9012.         Image: Denis 147 PM         A analytics         Image: Denis 147 PM         A analytics         Image: Denis 147 PM         Intrifying subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and the treased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and the treased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordin			
DECREASED HEMOGLOBIN ['AE':AETERM'         DECREASED HEMOGLOBIN FROM BASELINE ['AE':AETER         Image: Construction of the subjects with adverse events [[[AE':AETERM::DECREASED HEMOGLOBIN]]]         Image: Construction of the subjects with DECREASED HEMOGLOBIN]]         Image: Construction of the subjects with DECREASED HEMOGLOBIN]]         Image: Construction of the subjects with DECREASED HEMOGLOBIN]         Image: Construction of the subjects with DECREASED HEMOGLOBIN]         Image: Construction of the subjects with DECREASED HEMOGLOBIN]         Image: Construction of the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject IDs:         Image: Construction of the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject IDs:         Image: Construction of the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject IDs:         Image: Construction of the subjects with decreased hemoglobin belowing subjects of the drugs being tested. By pinpointing these subjects, researchers and naive the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and adjust dosages or treatment p	DECREASED HEMOGLOBIN   AE'.AETERM'         DECREASED HEMOGLOBIN   AE'.AETERM'         DECREASED HEMOGLOBIN FROM BASELINE   AE'.AETER         Image: Construction of the subjects with DECREASED HEMOGLOBIN[]]         Image: Construction of the subjects with DECREASED HEMOGLOBIN]]         Image: Construction of the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS203B001 and MAXIS-XYZ-008 studies are identified by the following subject ID::         Image: Construction of the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS203B001 and MAXIS-XYZ-008 studies are identified by the following subject ID::         Image: Construction of the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS203B001 and MAXIS-XYZ-008 studies are identified by the following subject ID::         Image: Construction of the subject of the subject of the dug being the subject of the dug being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the dug discovery process and dug dug dosages or treatment plans accordingl	~	maxis-demo 1/47 PM	
	DecReaseD HEMOGLOBIN FROM BASELINE   'AE', 'AETER         Image: Construction of the subjects of the subjects with DECREASED HEMOGLOBIN]]]         Image: Construction of the subjects with DECREASED HEMOGLOBIN]]         Image: Construction of the subjects with DECREASED HEMOGLOBIN]         Image: Construction of the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject ID:         Image: Construction of the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject ID:         Image: Construction of the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject ID:         Image: Construction of the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject ID:         Image: Construction of the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject ID:         Image: Construction of the discovery integes and the subjects researchers and analytics         Image: Construction of the discovery process and the subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and the discovery process and		A few options are found, please choose what you need	
<ul> <li>Penis 1-47 PM subjects ids adverse events [[[AE:'AETERM::DECREASED HEMOGLOBIN]]]</li> <li>maxis-demo 1-47 PM Based on the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS203B001 and MAXIS-XYZ-006 studies are identified by the following subject ID: MS203B001-1234, MS203B001-5678, MAXIS-XYZ-006-9012.</li> <li>Report AI analytics</li> <li>Denis 1-47 PM Al analytics</li> <li>maxis-demo 1-47 PM Identifying subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and</li> </ul>	<ul> <li>Penis 1:47 PM subjects ids adverse events [[[AE':AETERM:DECREASED HEMOGLOBIN]]]</li> <li>maxis-demo 1:47 PM Based on the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS203B001 and MAXIS-XYZ-008 studies are identified by the following subject ID: MS203B001-1234, MS203B001-5678, MAXIS-XYZ-008-9012.</li> <li>Report Alanalytics</li> <li>Denis 1:47 PM Al analytics</li> <li>maxis-demo 1:47 PM Identifying subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and Type a message</li> </ul>		DECREASED HEMOGLOBIN ['AE':AETERM'	
subjects ids adverse events [[[^AE`:AETERM:DECREASED HEMOGLOBIN]]]	subjects ids adverse events [[[AE:XETERM:]DECREASED HEMOGLOBIN]]]  maxis-demo 1xP PM Based on the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject IDs: MS2038001-1234, MS2038001-5678, MAXIS-XYZ-008-9012.  Performation of the data and the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject IDs: MS2038001-1234, MS2038001-5678, MAXIS-XYZ-008-9012.  Performation of the data and the subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and Type a message		DECREASED HEMOGLOBIN FROM BASELINE   "AE". AETER	
<ul> <li>maxis-demo 1:47 PM Based on the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject ID:: MS203B001-1234, MS203B001-5678, MAXIS-XYZ-008-9012.</li> <li>Report Al analytics</li> <li>Denis 1:47 PM Al analytics</li> <li>maxis-demo 1:47 PM Identifying subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and</li> </ul>	<ul> <li>maxis-demo 147 PM</li> <li>Based on the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject ID: MS2038001-1234, MS2038001-5678, MAXIS-XYZ-008-9012.</li> <li>Report Al analytics</li> <li>Denis 147 PM Al analytics</li> <li>maxis-demo 147 PM Ganais-demo 147 PM Hultifying subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and Type a message</li> </ul>	P.		
Based on the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS2038001 and MAXIS-XYZ-008 studies are identified by the following subject IDs: MS2038001-1234, MS2038001-5078, MAXIS-XYZ-008-9012.  Report Al analytics  Main analytics  Maxis-demo 1x7 PM Al analytics  Maxis-demo 1x7 PM Identifying subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and	Based on the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS203B001 and MAXIS-XYZ-008 studies are identified by the following subject IDs: MS203B001-1234, MS203B001-5678, MAXIS-XYZ-008-9012. Report Al analytics maxis-demo 147 PM Identifying subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and Type a message	()		
Denis 147 PM     Al analytics     M     identifying subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these     subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and	Denis 147 PM Al analytics     maxis-demo 147 PM discrete and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and Type a message		Based on the data, the subjects with DECREASED HEMOGLOBIN and Domain AE in the MS203B001 and MAXIS-XYZ-008 studies are identified by the following subject IDs:	
Al analytics	Al analytics		Report Al analytics	
maxis-demo 1x7 PM Identifying subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and	maxis-demo 147 PM Identifying subjects with decreased hemoglobin levels in medical trials is crucial in understanding the efficacy and safety of the drugs being tested. By pinpointing these subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and Type a message	•		~
subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and	subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and			9
			subjects, researchers can analyze the potential side effects and adjust dosages or treatment plans accordingly. This data can help accelerate the drug discovery process and	
Type a message			Type a message	
₩ ℓ © ፼ ₽ ◊ ♀ & Δ ₽ ₩ ··· ●			∥ ∥ ☺  ټ ♥ ♀ ᆭ ᡌ ฿ …	



### Why NLSQL?

NLSQL is a powerful natural language processing tool designed to revolutionise the way Clinical Research Organizations (CROs) analyse and interpret clinical trial results. By leveraging Al-driven technology, NLSQL enables users to access and analyse complex data sets using simple, intuitive questions in Microsoft Teams. This simplifies data access and analysis, save time and resources, and support better decision-making, ultimately leading to accelerated drug discoveries.





Precise



Secure No sensitive data transfer outside



Compatible Fits existing IT environment

#### Simple Easy as Google search

Up to 100% accuracy. Best rate in class.

### What do we need?

We are looking for further R&D collaboration project with a CRO or other healthcare research provider with a view to validating our prototype using partner's clinical data ahead of the launch of our commercial product.

# Learnings from the projects:



Innovate UK NLSQL has received a funding from German authority to develop a medical data search tool for faster clinical decision making based on better ICU patients records accessibility.

NLSQL received a InnovateUK funding for an innovative prototype development focused on future tool for faster clinical trials result analytics.



P4 Precision Medicine Acceleration program. Conducted research and custdev interviews with NHS Chief Data Officer.